Research in context
Evidence before this study
We searched PubMed for articles published in English between Jan 1, 1990, and June 1, 2017, with combinations of the search terms “Alzheimer's disease”, “dementia”, “cumulative incidence”, “age at onset”, “genetic risk score”, “APOE”, “risk”, and “lifetime risk”. We found that in case-control studies, genetic risk scores of common genetic variants were significantly associated with Alzheimer's disease and age at onset beyond APOE genotypes. In these studies, genetic risk scores improve classification of cases and controls and might facilitate the identification of individuals at high risk and their inclusion in presymptomatic Alzheimer's disease treatment or prevention trials. However, to translate findings into practice, the combined effect of these variants needs to be validated in large community-based cohort studies that assess incident Alzheimer's disease and all-cause dementia, while controlling for competing risk of death by other causes than dementia.
Added value of this study
Our study shows that the small effect of common genetic variants together significantly modify the risk of Alzheimer's disease and all-cause dementia, and partly account for the variability in the age at onset, above and beyond the APOE genotype. Shifts in age at onset translated into a higher risk of Alzheimer's disease and dementia at all ages. The joint effect of common genetic variants on cumulative risk of Alzheimer's disease is most profound in APOE ε4 carriers. On the basis of all variants, we were able to stratify individuals into risk groups from very low (4·1% by 85 years) to extremely high (62·7%) cumulative risk of Alzheimer's disease.
Implications of all the available evidence
To our knowledge, this is the first time that the the potential of genetic variants beyond APOE in determining cumulative risk of Alzheimer's disease has been shown in a large community-based cohort. Including genetic variants beyond APOE could contribute towards better risk stratification in the community, facilitating planning of feasible and efficient preventive and curative clinical trials.